Browse the full Event Guide to discover:
35+
industry leading speakers from the likes of Biogen, Amylyx, Novartis, Sanofi, Takeda, UCB, Denali and AbbVie
6
hours of intimate pre-conference workshop discussions, delving into TDP-43 based biomarkers, combination therapy and novel surrogate endpoints advancing beyond ALSFRS-R
8+
hours of dedicated networking time across speed networking, roundtable discussions, panels and more
1
scientific poster session, giving you the opportunity to display your own research to this diverse audience of discovery, preclinical and clinical ALS experts
Exclusive Insights from the Likes Of:
- Aarti Sharma, Associate Director, Motor Neuron Diseases, Regeneron
- Arti Patel, Principal Scientist II, Program Lead, Neuroscience, Novartis
- Mansuo Lu Shannon, Chief Scientific Officer, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly
- Bijan Nejadnik, Head of Global Development, Regulatory Affairs & QA, Mitsubishi Tanabe Pharma America
- Petra Duda, Senior Executive Director, Clinical Research & Global Development Lead, UCB
- Neta Zach, Head, Neuroscience Experimental Medicine, Takeda
Having trouble downloading the brochure?
Let us know and we’ll email it to you instead
Companies On The Program:
